Pharmaceutical companies are increasingly outsourcing their preclinical research and development to external structures. This subcontracting to public laboratories or service providers represents a significant potential market and therefore a real opportunity for economic development. The area of research concerns inflammation, both neuroinflammation and pulmonary or gastrointestinal inflammation. Severe inflammatory diseases such as asthma or chronic obstructive pulmonary bronchitis (COPD) are steadily increasing. Inflammatory cytokines are at the heart of these pathologies. Pharmaceutical companies have been looking for decades to develop cytokine inhibitors, but only biomedicines such as antibodies have actually proven their effectiveness to date. Whole parts are still to be discovered, as evidenced by the recent discovery of new cells, innate lymphoid cells (ILCs), or more recently cytosolic receptors of nucleic acids such as DNA, which activate the cGAS/STING pathways and play a central role in the inflammatory responses of type I interferons. One of the strengths of the laboratory is its expertise in both inflammatory and infectious pathologies, and a dual competence in immunology but also in neurobiology that allows a cross-analysis of the involvement of new pathways of regulation in these two fields...